Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Hexaethylene Glycol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.69 |
| ▸ | TSHR | P16473 | 3/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.62 |
| ▸ | THRB | P10828 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | PPARD | Q03181 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | APP | P05067 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | FDPS | P14324 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pentaethylene Glycol SCHEMBL1627452 | 1.00 | MEN1 (0.69) | MEN1KMT2ATSHRMAPK1THRB | |
| Phosphoric Acid SCHEMBL899139 | 1.00 | MEN1 (0.69) | MEN1KMT2ATSHRMAPK1THRB | |
| Triethylene Glycol SCHEMBL1573538 | 1.00 | MEN1 (0.69) | MEN1KMT2ATSHRMAPK1THRB | |
| Triethylene Glycol SCHEMBL816783 | 1.00 | MEN1 (0.69) | MEN1KMT2ATSHRMAPK1THRB | |
| Tetraethylene Glycol SCHEMBL236335 | 1.00 | MEN1 (0.69) | MEN1KMT2ATSHRMAPK1THRB | |
| Triethylene Glycol SCHEMBL874011 | 1.00 | MEN1 (0.69) | MEN1KMT2ATSHRMAPK1THRB | |
| Triethylene Glycol SCHEMBL854457 | 1.00 | MEN1 (0.69) | MEN1KMT2ATSHRMAPK1THRB | |
| Di(Hydroxyethyl)Ether SCHEMBL125344 | 0.97 | TSHR (0.67) | MEN1KMT2ATSHRMAPK1THRB | |
| Di(Hydroxyethyl)Ether SCHEMBL28090651 | 0.97 | TSHR (0.67) | MEN1KMT2ATSHRMAPK1THRB | |
| Di(Hydroxyethyl)Ether SCHEMBL8621256 | 0.97 | TSHR (0.67) | MEN1KMT2ATSHRMAPK1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220000900-A1 | Oligonucleotide Analogues Incorporating 5-Aza-Cytosine Therein | ASTEX PHARMACEUTICALS INC (US) | 2022-01-06 | — | — | US | claimed |
| EP-2944646-A1 | Oligonucleotide analogues incorporating 5-aza-cytosine therein | Astex Pharmaceuticals, Inc. (US) | 2015-11-18 | — | — | EP | claimed |
| EP-1943264-B1 | OLIGONUCLEOTIDE ANALOGUES INCORPORATING 5-AZA-CYTOSINE THEREIN | ASTEX PHARMACEUTICALS INC (US) | 2015-07-29 | — | — | EP | claimed |
| EP-1325151-B1 | IMPROVED BINDING INTERACTIONS IN DIPSTICK ASSAYS | DIAGNOSTICS FOR THE REAL WORLD LTD (US) | 2011-08-24 | — | — | EP | claimed |
| US-7927781-B2 | Photosensitive resin composition, method for preparing the same, and dry film resist comprising the same | DONGJIN SEMICHEM CO., LTD. (KR) | 2011-04-19 | — | — | US | claimed |
| US-20100215729-A1 | OLIGONUCLEOTIDE ANALOGUES INCORPORATING 5-AZA-CYTOSINE THEREIN | SUPERGEN, INC. | 2010-08-26 | — | — | US | claimed |
| US-7700567-B2 | methylation modulators; phosphoramidite building blocks; for treating cancer and hematological disorders | SUPERGEN, INC. (US) | 2010-04-20 | — | — | US | claimed |
| US-20090136872-A1 | PHOTOSENSITIVE RESIN COMPOSITION, METHOD FOR PREPARING THE SAME, AND DRY FILM RESIST COMPRISING THE SAME | DONGJIN SEMICHEM CO., LTD. (KR) | 2009-05-28 | — | — | US | claimed |
| EP-1943264-A2 | OLIGONUCLEOTIDE ANALOGUES INCORPORATING 5-AZA-CYTOSINE THEREIN | SuperGen, Inc. (US) | 2008-07-16 | — | — | EP | claimed |
| WO-2007041071-A2 | OLIGONUCLEOTIDE ANALOGUES INCORPORATING 5-AZA-CYTOSINE THEREIN | SUPERGEN, INC. (US) | 2007-04-12 | — | — | WO | claimed |
| US-20070072796-A1 | methylation modulators; phosphoramidite building blocks; for treating cancer and hematological disorders | ASTEX PHARMACEUTICALS, INC. | 2007-03-29 | — | — | US | claimed |
| US-20060141392-A1 | Photosensitive resin composition, method for preparing the same, and dry film resist comprising the same | DONGJIN SEMICHEM CO., LTD. (KR) | 2006-06-29 | — | — | US | claimed |
| US-20040072176-A1 | Binding interactions in dipstick assays | DIAGNOSTICS FOR THE REAL WORLD, LTD. | 2004-04-15 | — | — | US | claimed |
| US-20040053256-A1 | Detection signal and capture in dipstick assays | DIAGNOSTICS FOR THE REAL WORLD, LTD. | 2004-03-18 | — | — | US | claimed |
| EP-1325151-A2 | IMPROVED BINDING INTERACTIONS IN DIPSTICK ASSAYS | Lee, Helen (GB) | 2003-07-09 | — | — | EP | claimed |
| EP-1301627-A2 | IMPROVED DETECTION SIGNAL AND CAPTURE IN DIPSTICK ASSAYS | Lee, Helen (GB) | 2003-04-16 | — | — | EP | claimed |
| WO-2002004667-A2 | IMPROVED DETECTION SIGNAL AND CAPTURE IN DIPSTICK ASSAYS | LEE HELEN (GB) | 2002-01-17 | — | — | WO | claimed |
| WO-2002004671-A2 | IMPROVED BINDING INTERACTIONS IN DIPSTICK ASSAYS | LEE HELEN (GB) | 2002-01-17 | — | — | WO | claimed |
| EP-4714453-A1 | USE OF STRUCTURE FOR NUCLEIC ACID DELIVERY IN TREATMENT OF HEMATOPOIETIC TUMOR | Japan Science and Technology Agency (JP) | 2026-03-25 | — | — | EP | disclosed |
| EP-0978561-A1 | Antisense oligonucleotides for the inhibition of VEGF expression | Hoechst Marion Roussel Deutschland GmbH (DE) | 2000-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220000900-A1 | Oligonucleotide Analogues Incorporating 5-Aza-Cytosine Therein | DCTD, DNMT3B, NT5C3B | MEN1 2864/4885KMT2A 850/4885TSHR 1934/4885 |
| US-20100215729-A1 | OLIGONUCLEOTIDE ANALOGUES INCORPORATING 5-AZA-CYTOSINE THEREIN | DCTD, DNMT3B, NT5C3B | MEN1 2864/4885KMT2A 850/4885TSHR 1934/4885 |
| US-20070072796-A1 | methylation modulators; phosphoramidite building blocks; for treating cancer and hematological disorders | DCTD, DNMT3B, NT5C3B | MEN1 2109/4885KMT2A 428/4885TSHR 2466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.